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In patients with chronic inflammatory demyelinating polyneuropathy (CIDP), intravenous immu-
noglobulin (IVIG) is recommended to be periodically reduced to assess the need for ongoing
therapy. However, little is known about the effectiveness of restabilization with IVIG in patients
who worsen after IVIG withdrawal. In the Polyneuropathy And Treatment with Hizentra (PATH)
study, the pre-randomization period included sudden stopping of IVIG followed by 12 weeks of
observation. Those deteriorating were then restabilized with IVIG. Of 245 subjects who stopped
IVIG, 28 did not show signs of clinical deterioration within 12 weeks. Two hundred and seven
received IVIG restabilization with an induction dose of 2 g/kg bodyweight (bw) IgPro10
(Privigen, CSL Behring, King of Prussia, Pennsylvania) and maintenance doses of 1 g/kg bw
every 3 weeks for up to 13 weeks. Signs of clinical improvement were seen in almost all
(n = 188; 91%) subjects. During IVIG restabilization, 35 subjects either did not show CIDP sta-
bility (n = 21, analyzed as n = 22 as an additional subject was randomized in error) or withdrew
for other reasons (n = 14). Of the 22 subjects who did not achieve clinical stability, follow-up
information in 16 subjects after an additional 4 weeks was obtained. Nine subjects were
reported to have improved, leaving a maximum of 27 subjects (13%) who either showed no
signs of clinical improvement during the restabilization phase and 4 weeks post-study or with-
drew for other reasons. In conclusion, sudden IVIG withdrawal was effective in detecting ongo-
ing immunoglobulin G dependency with a small risk for subjects not returning to their baseline
17 weeks after withdrawal.
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1 | INTRODUCTION
Chronic inflammatory demyelinating polyneuropathy (CIDP), a rare
immune-mediated disease of the peripheral nervous system, has a grad-
ually worsening or, less commonly, a relapsing–remitting course.1 Intra-
venous immunoglobulin (IVIG) is a treatment option as outlined in the
European Federation of Neurological Societies and Peripheral Nerve
Society (EFNS/PNS) 2010 guidelines.2 While complete remission after
short-term therapy occurs in some patients,3 others require extended
therapy. Because patients may go into remission after longer periods of
IVIG treatment, and IVIG is expensive, it is recommended that all thera-
pies, and especially IVIG, be periodically reduced or withdrawn to
assess ongoing need for continued therapy, or whether the disease has
become inactive and therapy is no longer needed. In case symptoms
return after immunoglobulin (Ig) withdrawal, treatment is reinstated. To
our knowledge, little is known about the outcome of such withdrawal
trials and the effectiveness of reinitiation of therapy.
In the Polyneuropathy And Treatment with Hizentra (PATH)
study4 before the randomized and blinded portion of the study, sub-
jects underwent a period of sudden, unblinded IVIG withdrawal fol-
lowed by 13 weeks of close observation and, if they worsened,
immediate IVIG restabilization. This was done to ensure that subjects
who entered the next phase of the study had active disease. This
enrichment strategy was implemented as a consequence of previous
trials where IVIG could be reduced without change in symptoms5 or
where subjects who were administered placebo after a period of IVIG
treatment showed a low rate of relapse.6
The sequelae of stopping IVIG treatment in otherwise stable CIDP
patients has not been examined in a prospective study. This report
focuses on the questions of whether a sudden treatment stop is feasible,
which clinical measures can be used in combination to detect subtle yet
meaningful deterioration, how quickly subjects recover after reinitiating
therapy, and to what extent recovery is achieved within 17 weeks.
2 | METHODS AND MATERIALS
The details of the PATH trial have been previously published.7 In
brief, adult subjects with definite or probable CIDP,2 all being treated
with IVIG before enrollment were eligible for this study. After
screening, IVIG was withheld until clinical deterioration occurred.
Subjects who did not show any signs of clinical worsening after
12 weeks of IVIG withdrawal were discontinued from the study as
they were assumed to have inactive disease. On deterioration, sub-
jects entered the IVIG (IgPro10, Privigen, CSL Behring) restabilization
period to receive one induction dose of 2 g/kg bodyweight (bw) given
over 2 to 5 days and an additional 3 to 4 maintenance doses of
1 g/kg bw every 3 weeks. Subjects who were not restabilized were
discontinued from the study. A 4-week post-study follow-up was
conducted for those subjects. Subjects who recovered and were sta-
ble at the last two visits of the IVIG restabilization period were ran-
domized to subcutaneous Ig (SCIG [IgPro20, Hizentra; CSL Behring])
or placebo (Figure 1).
Clinical deterioration was defined as an increase in adjusted
inflammatory neuropathy cause and treatment (INCAT) total score by
≥1 point,6,8 a decrease in inflammatory Rasch-built overall disability
scale (I-RODS) total score by ≥4 points,9 or a decrease in mean grip
strength by ≥8 kilopascals [kPa].10 I-RODS and grip strength measures
were used to detect IVIG dependency only after a protocol change.
Clinical improvement was assessed with the same measures
including a decrease in the Medical Research Council (MRC) sum
score (range 0-80) by ≥3 points compared with the reference visit
(prior to first IVIG restabilization dose).11
Subjects were trained during screening to document I-RODS
score and grip strength measurements daily in a diary and were pro-
vided with a Martin Vigorimeter. In addition, subjects' status was
assessed every 2 weeks either during a site visit or telephone call.
Subjects could also contact the site at any time in case of deteriora-
tion outside of the defined contact time points.
This study was conducted in accordance with the International
Conference on Harmonization Good Clinical Practice guidelines and
the Declaration of Helsinki. The study protocol and all other study-
related documents were reviewed and approved by the local Indepen-
dent Ethics Committees. Written informed consent was obtained
from all subjects before they started the study. This study is registered
with Clinicaltrials.gov, number NCT01545076.
Post-randomization PhasePre-randomization Phase
Stop
Stop
Stop
Screening
IVIG 
withdrawal
IVIG (IgPro10)
restabilization
Placebo
No deterioration
after 12 weeks
Not restabilized
after 13 weeks
CIDP relapse
within 24 weeks
Deterioration
IgPro20 0.2 g/kg/week
IgPro20 0.4 g/kg/week
IgPro10
Rescue
FIGURE 1 Study design. Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; IgPro10, 10% intravenous immunoglobulin
preparation; IgPro20, 20% subcutaneous immunoglobulin preparation; IVIG, intravenous immunoglobulin. Note: “Stop” indicates that subject was
discontinued from the study after all study completion assessments were performed
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2.1 | Statistical methodology
The pre-randomization phase (IVIG withdrawal and restabilization)
served as an enrichment strategy of the PATH study. The objective of
the IgPro10 restabilization period was to investigate the efficacy and
safety of IgPro10 (a secondary objective of the PATH trial). No formal
sample size determination was performed for the pre-randomization
phase. Efficacy and safety were determined in the pre-randomization
safety data set (PSDS), defined as all subjects enrolled into the study
who received at least one dose of IgPro10.
The efficacy endpoints were based on the number and percentage
of subjects with improvement for the efficacy scores (adjusted INCAT
total score, I-RODS centile score, mean grip strength, and MRC sum
score). Efficacy parameters were summarized by visit, using descriptive
statistics, and changes from Reference Visit were calculated. The Refer-
ence Visit was the last visit before entering the restabilization period.
The safety analysis was based on the PSDS. Descriptive statistics
were calculated for all parameters.
3 | RESULTS
3.1 | IVIG withdrawal period
When subjects entered the study and passed the screening phase,
their regular IVIG treatment was stopped until signs of clinical deterio-
ration were detected. A total of 245 subjects entered this IVIG with-
drawal period. Subjects received their last IVIG cycle either at any
time before study entry (original protocol) or at the end of the screen-
ing period (protocol amendment).
In total, 28 (11.4%) subjects did not show any signs of clinical dete-
rioration and were discontinued from the study (Figure 2). A further
10 subjects withdrew from this phase for other reasons. Clinical deteri-
oration was shown by adjusted INCAT score (≥1 point increase) in
73% of subjects; the remaining subjects showed deterioration by either
I-RODS or grip strength. Deterioration occurred mostly in the first
8 weeks after IVIG withdrawal (median 70 [42–105] days, n = 156
[64%]). In total, 207 subjects entered the IgPro10 restabilization period.
3.2 | IgPro10 restabilization period
Table 1 shows the subject demographics and disease characteristics of
all 207 subjects entering the IgPro10 restabilization period. Approxi-
mately 91% of subjects who deteriorated only in adjusted INCAT score
during the withdrawal period (n = 151) improved their INCAT score dur-
ing the restabilization period (Table 2). Of all subjects entering this study
period, 91% showed improvement in at least one of the pre-specified
outcome measures (Table 3). Almost all of the subjects who showed
improvement had improved after three doses of IgPro10, that is, by
Week 10 (99%). Approximately 21% of improving subjects had a better
score (adjusted INCAT) compared with screening, prior to IVIG with-
drawal. Figure 3 shows the pattern of all four scores over the first
10 weeks of the restabilization period. Subjects showed a mean decline
between baseline and IVIG withdrawal and improved mean scores dur-
ing IVIG restabilization compared with baseline. First improvement,
regardless of the outcome measure, occurred within a median time of
23 days, that is, at the first assessment after the first IVIG dose (Table 3).
In total, 83% of subjects remained clinically stable at the end of
the 10- to 13-week restabilization period by the definition of the pro-
tocol, which required the same adjusted INCAT score at the last two
visits which could not be worse when compared with their baseline
adjusted INCAT score. These stabilized subjects were subsequently
randomized to SCIG or placebo.4
Screened
N = 276
IVIG Withdrawal Period 
N = 245
IgPro10 Restabilization Period (PSDS) 
N = 207
CIDP stability 
N = 171
Randomized to IgPro20/placebo 
N = 172*
PP-PSDS†
N = 195
Not eligible N = 31 (11%)
Withdrawn N = 35
Subjects did not return to at least the 
INCAT score at screening* N = 21 
Withdrawal for other reasons N = 14
Withdrawn N = 38
No CIDP deterioration N = 28 
Withdrawal for other reasons N = 10
FIGURE 2 Subject disposition. Per investigator, one additional subject met the criteria to enter the IgPro10 restabilization period (N = 208), but
the subject withdrew consent and did not receive any IgPro10 (treated count N = 207). A total of 13 subjects were rescreened. Abbreviations:
CIDP, chronic inflammatory demyelinating polyneuropathy; IgPro10, 10% intravenous immunoglobulin preparation; IgPro20, 20% subcutaneous
immunoglobulin preparation; IVIG, intravenous immunoglobulin; N, number of subjects; PP-PSDS, per-protocol pre-randomization safety data set;
PSDS, pre-randomization safety data set. *An additional subject did not return to at least the inflammatory neuropathy cause and treatment
(INCAT) score at screening, but was randomly allocated in error. †Reasons for exclusion of 12 subjects from the PSDS: five subjects did not
demonstrate CIDP deterioration during the IVIG withdrawal period, but were transitioned to the IgPro10 restabilization period; five subjects took
prohibited concomitant medication during the pre-randomization phase; one subject received an increased loading dose during pre-randomization
phase; one subject took prohibited concomitant medication (nonstudy IVIG) during pre-randomization phase and received an increased loading
dose during pre-randomization phase
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Of the subjects treated with IVIG in the restabilization period,
35 (17%) either did not improve (n = 21 [analyzed as n = 22 to
include one later identified subject who had not returned to his/her
screening INCAT score and was randomized in error]) or could not
be stabilized as they withdrew for other reasons (n = 14), while
171 (83%) subjects achieved CIDP stability during this period
(Figure 2). Demographic and disease characteristics of the 22 (11%)
non-improving subjects are provided in Table 1. There were no rele-
vant differences observed between the overall restabilized popula-
tion and those who did not reach CIDP stability. Subjects had a
mean adjusted INCAT score of 4.2 (SD 1.6) after IVIG withdrawal,
which improved by 0.4 points (SD 1.4) at the last observation.
Follow-up information was obtained 4 weeks post study in 16/22
subjects. In nine subjects, improvement based on clinical judgment
was identified. Therefore, 13% (27 subjects) either showed no signs
of clinical improvement (n = 13 which includes six subjects who did
not respond to the follow-up questionnaire) during the restabiliza-
tion phase and 4-week post-study follow-up or withdrew from the
study for other reasons (n = 14).
3.3 | Safety
Out of 207 subjects in the IVIG restabilization period, 100 (48.3%)
experienced a total of 284 adverse events, and causally related
adverse events were experienced by 28% of the subjects. The most
common adverse events occurring in >5% of subjects were headache,
nasopharyngitis, and nausea (Table 4). There were seven related seri-
ous adverse events (allergic reaction, pulmonary embolism, increase in
diastolic blood pressure, exacerbation of CIDP, worsening of respira-
tory failure due to chronic obstructive pulmonary disease, rash, and
worsening of migraine).
4 | DISCUSSION
The PATH study design mandated an initial determination of IVIG
dependence by stopping IVIG treatment for a maximum of 12 weeks
and frequently assessing potential clinical deterioration by different
outcome measures. Experiences from the IGIV-C CIDP efficacy (ICE)
trial,6 where 58% of placebo subjects did not deteriorate within
24 weeks (equivalent to a blinded IVIG withdrawal) and the random-
ized, controlled trial of methotrexate for CIDP (RMC) trial,5 where
reduction of IVIG dose by ≥20% also did not lead to clinical deteriora-
tion, motivated this trial design. With 245 subjects included, the PATH
study provided a large cohort in which IVIG withdrawal and restabili-
zation was studied prospectively.
The study was successful in identifying approximately 11% of
subjects not requiring immunoglobulin G (IgG) treatment within
12 weeks, that is, showing no signs of clinical deterioration, neither by
adjusted INCAT score, I-RODS, nor daily measured grip strength. An
TABLE 1 Demographics and disease characteristics of subjects
Subjects entering the
IVIG withdrawal
period, N = 245
Subjects showing
no deterioration within
the withdrawal period, N = 28
Subjects with
deterioration
entering
restabilization,
N = 207 (PSDS)
Subjects showing
restabilization on
IVIG, N = 171
(ITTS, N = 172)a,b
Subjects not
showing improvement,
N = 22 (PSDS)b
Age (years), median (min, max) 58.2 (24.7, 82.7) 56.7 (26.8, 82.4) 58.2 (24.7, 82.7) 57.8 (24.7, 82.7) 58.6 (30.8, 77.5)
Sex, n (%)
Male 162 (66) 22 (79) 131 (63) 110 (64) 13 (59)
Female 83 (34) 6 (21) 76 (37) 62 (36) 9 (41)
Weight (kg), median (min, max) 83 (41.8, 145.8) 89 (56.5, 118.0) 82 (41.8, 133.0) 82 (41.7, 133.0) 79 (43.7, 111.9)
BMIc (kg/m2), median (min,
max)
27 (17.6, 49.4) 27 (20.8, 35.1) 27 (17.6, 49.4) 27 (17.6, 49.4)
Time since initial CIDP
diagnosis (years)d
Mean (SD) 4.57 (5.1) 4.28 (5.0) 4.66 (5.2) 4.73 (5.4) 4.84 (4.6)
Median (min, max) 2.8 (0.1, 33.6) 2.7 (0.3, 19.2) 3.0 (0.1, 33.5) 3.0 (0.1, 33.5) 3.2 (0.2, 16.4)
EFNS/PNS CIDP diagnostic
criteria, N (%)
Definite 221 (90) 26 (93) 185 (89) 157 (91) 19 (86)
Probable 24 (10) 2 (7) 22 (11) 15 (9) 3 (14)
Screening INCAT total score,
points
Mean (SD) 2.7 (1.7) 2.4 (1.6) 2.7 (1.7) 2.3 (1.7) 2.8 (2.3)
Median (min, max) 3.0 (0.0, 8.0) 2.0 (0.0, 6.0) 3.0 (0.0, 8.0) 2.0 (0.0, 7.0) 3.0 (0.0, 8.0)
Abbreviations: BMI, body mass index; CIDP, chronic inflammatory demyelinating polyneuropathy; EFNS, European Federation of Neurological Societies;
INCAT, inflammatory neuropathy cause and treatment; ITTS, intention to treat set; max, maximum; min, minimum; N, number of subjects; PNS, Peripheral
Nerve Society; PSDS, pre-randomization safety data set; SD, standard deviation.
a Data for intention to treat set (ITTS).
b Analysis includes one subject who was randomized in error.
c BMI at screening = weight at screening (kg) / (height at screening [m])2. For BMI, N = 243 or 205, respectively.
d Time since initial diagnosis of CIDP (years) = (date of informed consent – date of initial diagnosis + 1) / 365.25.
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additional 2% of subjects also did not show signs of deterioration but
left this study phase due to withdrawal of consent. Reasons for the
low number of IVIG-independent subjects may lie in pre-selection of
subjects and limited observation time.
Most (91%) of the 207 subjects who were treated during the
restabilization phase improved in at least one of the clinical measures
after treatment with IgPro10, and 83% remained stable according to
the clinical measures at the end of this phase. Stabilization was
defined as showing the same or better adjusted INCAT score at two
consecutive visits after improvement. The restabilization phase was
10 to 13 weeks long as this was considered the minimum time for
previously IVIG-treated subjects to show improvement and be stabi-
lized after previous deterioration.12 However, it may have been too
short for subjects who deteriorated later in the IVIG withdrawal
period and as such, could not improve in the short timeframe of the
IVIG restabilization period. Of the subjects showing improvement,
21% had a better lowest total adjusted INCAT score in the IVIG resta-
bilization period when compared to their INCAT score at screening.
This could infer under-treatment of subjects on stable doses of IVIG.
Initially, 22/207 subjects did not return to their baseline status during
the 13-week IgPro10 treatment phase. Of these, at a further follow-
up 4 weeks after completing the study, an additional nine subjects
(4%) had shown improvements; and a maximum of 13 subjects (6%)
might not have returned to their baseline level since no further infor-
mation was available.
What are the practical implications of these results? Sudden with-
drawal of IVIG in an open fashion is a feasible method to assess ongo-
ing disease activity and the need for IVIG. In our study, we limited the
time to assess IgG dependency to 12 weeks, and we therefore might
have excluded some IgG-dependent subjects, who would have only
shown dependence beyond 12 weeks. We initially used adjusted
INCAT score (≥1 point increase) as a measure of disease impact. A
protocol change was introduced to recruit additional subjects whose
deterioration was difficult to assess by adjusted INCAT score alone.
After the protocol change, adjusted INCAT score along with I-RODS
(≥4 point decrease), or grip strength (≥8 kPa decrease) were used to
increase the sensitivity for early detection of worsening and to detect
ongoing disease activity. The cutoffs were a compromise between
allowing detection of relevant disease worsening and assuring that
recurrence of symptoms was temporary, that is, reversible after reini-
tiation of therapy. The trial was not designed to evaluate the sensitiv-
ity or specificity of modified INCAT, I-RODS, or grip strength with
their respective cutoffs for the evaluation of Ig dependence in CIDP
after IVIG withdrawal.
The main reason for excluding those with inactive disease was to
increase the likelihood for placebo subjects to relapse during the ran-
domized study phase with the SCIG IgPro20. The final study results of
PATH,4 with 63% of placebo-treated subjects showing CIDP relapse
(56%) or withdrawal for other reasons (7%) may still seem low but was
in the expected pre-defined range and higher than in an IVIG placebo-
controlled trial (42%, ICE trial6). The IVIG restabilization phase that
preceded the SCIG randomized phase may have contributed to this
result. All subjects received a 2 g/kg bw induction dose followed by a
1 g/kg bw 3-weekly maintenance dose, and a carry-over effect of IVIG
into the subcutaneous phase cannot be ruled out, potentially contrib-
uting to the placebo response. Similar observations were made in the
ICE trial,6 where after a phase of IVIG treatment, only 42% of pla-
cebo-treated subjects had a relapse during the randomized withdrawal
phase. The restabilization phase also showed that more than 90% of
subjects returned to or improved beyond their baseline level at study
entry. The group that did not fully restabilize at least showed a ten-
dency towards improvement, however, we did not treat subjects lon-
ger than 13 weeks or formally follow them up for longer than 4 weeks
post-study.
In the Privigen Impact on Mobility and Autonomy (PRIMA) trial12
a similar IgG withdrawal period was performed (up to 10 weeks) for
those subjects on a previous regular IVIG regime. Following deteriora-
tion, subjects were given an IVIG IgPro10 induction dose (2 g/kg bw)
over 2 to 5 days, followed by up to 7 infusions (1 g/kg bw) at 3-week
intervals. In that study, 1/14 subjects (7%) did not show deterioration
TABLE 2 CIDP improvement and CIDP stability during IgPro10
restabilization period in relation to results of IVIG withdrawal period
(PSDS population)
IgPro10 restabilization
period
Number (%) of subjects, N = 207
IVIG withdrawal period
CIDP deterioration bya
No CIDP
deterioration
or withdrawal
from
study,b
INCAT total
score, N = 151
I-RODS total
score or mean
grip strength,
N = 49 N = 7
Improvement by
adjusted INCAT
scorec
137 (91) 10 (20) 4 (57)
No improvement by
adjusted INCAT
scorec
14 (9) 39 (80) 3 (43)
Improvement and CIDP
stability achieved
(based on adjusted
INCAT score)c,d
120 (80) 9 (18) 4 (57)
No improvement but
CIDP stability
achieved (based on
adjusted INCAT
score)c,d
4 (3) 32 (65) 2 (29)
Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy;
INCAT, inflammatory neuropathy cause and treatment; I-RODS, inflamma-
tory Rasch-built overall disability scale; IVIG, intravenous
immunoglobulin; N, number of subjects; PSDS, pre-randomization safety
data set.
a CIDP deterioration was defined as an increase in adjusted INCAT total
score by ≥1 point, a decrease in I-RODS total score by ≥4 points, or a
decrease in mean grip strength by ≥8 kPa.
b Subjects who did not demonstrate CIDP deterioration during the IVIG
withdrawal period but entered IgPro10 restabilization period (N = 3)
with an additional four subjects who had shown CIDP deterioration but
withdrew consent.
c Improvement was defined as a decrease in adjusted INCAT score by
≥1 point, an increase in I-RODS centile score by ≥4 points, an increase
in mean grip strength by ≥8 kPa, and an increase in MRC sum score by
≥3 points, as compared to the Reference Visit.
d CIDP stability occurred when CIDP status did not show a clinically mean-
ingful difference at the last two consecutive visits during the IgPro10
restabilization period. In addition, to be considered CIDP stable, the
CIDP status had to recover back to at least the status at Screening
(as assessed by adjusted INCAT score).
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in adjusted INCAT score and 3/13 (23%) did not return to their base-
line adjusted INCAT level. However, all subjects improved in either
grip strength or MRC score. In the ICE study, 58% did not show signs
of deterioration also measured by adjusted INCAT score at the end of
the 24-week randomized, blinded, withdrawal maintenance phase
after responding to IVIG in the first or second treatment phase. It is
not known whether these subjects deteriorated in other clinical mea-
sures or if their disease was inactive in that period. The fate of
relapsed subjects in the ICE study is also not known. In a randomized,
placebo-controlled study comparing IVIG to intravenous methylpred-
nisolone, 38% of subjects on previous IVIG worsened within 5 months
after treatment discontinuation (median 4 months, range
1–5 months),13 leading to the conclusion that deterioration after IVIG
suspension can occur later than assessment in our study occurred
(maximum 12 weeks). After 12 months, 54% of IVIG-treated subjects
did not require further therapy. Long-term follow-up of IVIG-treated
subjects revealed that approximately 86% would worsen within a
median follow-up time of 42 months (range 1–57 months) after ther-
apy discontinuation (median time to worsening 4.5 months, range
1–24 months).14
In conclusion, sudden IVIG withdrawal was effective in detecting
active disease and ongoing IgG dependency, with approximately five
TABLE 3 Time to first improvement (PSDS population)
Overall, N = 207
INCAT total score
I-RODS centile
score
Mean grip strength
(dominant hand) MRC sum score
First improvement
in any criteria
Number of events (improvements), n (%) 151 (73) 84 (41) 123 (59) 117 (57) 188 (91)
Number of censored observations, n (%)a 56 (27) 123 (59) 84 (41) 90 (44) 19 (9)
Time to first improvement, daysb
Median 26 71 65 65 23
95% CI 24, 41 66, 86 64, 66 64, 67 22, 23
Abbreviations: CI, confidence interval; INCAT, inflammatory neuropathy cause and treatment; I-RODS, inflammatory Rasch-built overall disability scale;
IVIG, intravenous immunoglobulin; MRC, Medical Research Council; N, number of subjects; PSDS, pre-randomization safety data set.
Improvement was defined as a decrease in adjusted INCAT score by ≥1 point, an increase in I-RODS centile score by ≥4 points, an increase in mean grip
strength by ≥8 kPa, and an increase in MRC sum score by ≥3 points, as compared to the Reference Visit (prior to first restabilization IVIG dose).
a Subjects without improvements were censored at the date of their last visit in the IgPro10 restabilization period.
b Using Kaplan-Meier estimation. Time to first improvement (days) = date of first improvement - date of first IVIG infusion.
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in every six subjects restabilizing during the 13-week restabilization
period following reinitiation of therapy.
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TABLE 4 Most common adverse events (PSDS population)
System organ class
preferred term
Number (%) of
subjects, N = 207
Number
of events
Rate/infusion,
N = 1620a
Any adverse event 100 (48.3) 284 0.175
Headache 34 (16.4) 53 0.033
Nasopharyngitis 12 (5.8) 12 0.007
Nausea 10 (4.8) 12 0.007
Hemolysisb 7 (3.4) 7 0.004
Hypertension 6 (2.9) 7 0.004
Rash 6 (2.9) 6 0.004
Vomiting 6 (2.9) 7 0.004
Back pain 5 (2.4) 5 0.003
Fall 5 (2.4) 5 0.003
Fatigue 5 (2.4) 11 0.007
Edema peripheral 5 (2.4) 5 0.003
Abbreviations: N, number of subjects; PSDS, pre-randomization safety
data set.
a Number of infusions.
b Two out of the seven hemolysis subjects met the laboratory criteria for
hemolysis, both from non-O blood groups.
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